Wei Yang

Wei Yang

Auto-generated profile, based on publicly available information

Wei Yang

Medical Research Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China; Guangdong Provincial Key Laboratory of Molecular Oncologic Pathology, Department of Pathology, School of Basic Medical Sciences, Southern Medical University, Guangzhou, China

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 March 2016 in Nature
Verified
Journal Article
Closed access
PDF file
WYWei Yang
Wei Yang
YBYibing Bai
Yibing Bai
YXYing Xiong
Ying Xiong
JZJin Zhang
Jin Zhang
SCShuokai Chen
Shuokai Chen
CXChenqi Xu
Chenqi Xu

2 December 2012 in Nature
Verified
Journal Article
Closed access
PDF file
XSXiaoshan Shi
Xiaoshan Shi
YBYunchen Bi
Yunchen Bi
WYWei Yang
Wei Yang
XGXingdong Guo
Xingdong Guo
YJYan Jiang
Yan Jiang
CXChenqi Xu
Chenqi Xu

3 July 2018 in Nature Communications
Verified
Journal Article
Open access
PDF file
WXWei Xiang
Wei Xiang
RSRongchen Shi
Rongchen Shi
XKXia Kang
Xia Kang
XZXuan Zhang
Xuan Zhang
PCPeng Chen
Peng Chen
HMHongming Miao
Hongming Miao
Metabolic reprogramming greatly contributes to the regulation of macrophage activation. However, the mechanism of lipid accumulation and the corresponding function in tumor-associated macrophages (TAMs) remain unclear. With primary investigation in colon cancer and confirmation in other cancer models, here we determine that deficiency of monoacylglycerol lipase (MGLL) results in lipid overload in TAMs. Functionally, macrophage MGLL inhibits CB2 cannabinoid receptor-dependent tumor progression in inoculated and genetic cancer models. Mechanistically, MGLL deficiency promotes CB2/TLR4-dependent macrophage activation, which further suppresses the function of tumor-associated CD8+ T cells. Treatment with CB2 antagonists delays tumor progression in inoculated and genetic cancer models. Finally, we verify that expression of macrophage MGLL is decreased in cancer tissues and positively correlated with the survival of cancer patients. Taken together, our findings identify MGLL as a switch for CB2/TLR4-dependent macrophage activation and provide potential targets for cancer therapy.

19 February 2021 in Protein & Cell
Verified
Journal Article
Open access
PDF file
JYJuanjuan Yuan
Juanjuan Yuan
TCTing Cai
Ting Cai
XZXiaojun Zheng
Xiaojun Zheng
YRYangzi Ren
Yangzi Ren
JQJingwen Qi
Jingwen Qi
WYWei Yang
Wei Yang
Metabolic regulation has been proven to play a critical role in T cell antitumor immunity. However, cholesterol metabolism as a key component of this regulation remains largely unexplored. Herein, we found that the low-density lipoprotein receptor (LDLR), which has been previously identified as a transporter for cholesterol, plays a pivotal role in regulating CD8+ T cell antitumor activity. Besides the involvement of cholesterol uptake which is mediated by LDLR in T cell priming and clonal expansion, we also found a non-canonical function of LDLR in CD8+ T cells: LDLR interacts with the T-cell receptor (TCR) complex and regulates TCR recycling and signaling, thus facilitating the effector function of cytotoxic T-lymphocytes (CTLs). Furthermore, we found that the tumor microenvironment (TME) downregulates CD8+ T cell LDLR level and TCR signaling via tumor cell-derived proprotein convertase subtilisin/kexin type 9 (PCSK9) which binds to LDLR and prevents the recycling of LDLR and TCR to the plasma membrane thus inhibits the effector function of CTLs. Moreover, genetic deletion or pharmacological inhibition of PCSK9 in tumor cells can enhance the antitumor activity of CD8+ T cells by alleviating the suppressive effect on CD8+ T cells and consequently inhibit tumor progression. While previously established as a hypercholesterolemia target, this study highlights PCSK9/LDLR as a potential target for cancer immunotherapy as well.

15 February 2013 in Development
Verified
Journal Article
Closed access
PDF file
BLBo Liu
Bo Liu
YLYuan-Feng Liu
Yuan-Feng Liu
YDYa-Rui Du
Ya-Rui Du
AMAndrei N. Mardaryev
Andrei N. Mardaryev
WYWei Yang
Wei Yang
GXGuo-Liang Xu
Guo-Liang Xu
Thymic epithelial cells (TECs) are the main component of the thymic stroma, which supports T-cell proliferation and repertoire selection. Here, we demonstrate that Cbx4, a Polycomb protein that is highly expressed in the thymic epithelium, has an essential and non-redundant role in thymic organogenesis. Targeted disruption of Cbx4 causes severe hypoplasia of the fetal thymus as a result of reduced thymocyte proliferation. Cell-specific deletion of Cbx4 shows that the compromised thymopoiesis is rooted in a defective epithelial compartment. Cbx4-deficient TECs exhibit impaired proliferative capacity, and the limited thymic epithelial architecture quickly deteriorates in postnatal mutant mice, leading to an almost complete blockade of T-cell development shortly after birth and markedly reduced peripheral T-cell populations in adult mice. Furthermore, we show that Cbx4 physically interacts and functionally correlates with p63, which is a transcriptional regulator that is proposed to be important for the maintenance of the stemness of epithelial progenitors. Together, these data establish Cbx4 as a crucial regulator for the generation and maintenance of the thymic epithelium and, hence, for thymocyte development.

23 October 2017 in Nature Structural & Molecular Biology
Verified
Journal Article
Closed access
PDF file
WYWei Yang
Wei Yang
WPWeiling Pan
Weiling Pan
SCShuokai Chen
Shuokai Chen
NTNicola Trendel
Nicola Trendel
SJShutan Jiang
Shutan Jiang
CXChenqi Xu
Chenqi Xu